Revenue ($USD) : $21,200,000,000
R&D spend : not available
Employees : 35,000
Fiscal year end : 12/31/22
CEO : Charlie Mills, CEO; Jim Boyle, CEO after Oct. 1, 2023

Medline sales were up roughly 5% year-over-year to $21.2 billion in 2022, enabling the privately held medtech giant to move up one spot in the MedTech Big 100 rankings.

Medline announced in June that it is promoting from within to fill CEO and president positions. Jim Boyle is taking over the corner office at Medline, effective Oct. 1. Boyle has been at Medline since 1996 and served as EVP since 2018, managing the company’s customer base of over 5,000 healthcare providers. Meanwhile, Jim Pigott will become president and chief operating officer. After more than 26 years of leadership, CEO Charlie Mills, President Andy Mills and COO Jim Abrams will retire from their current positions. They’ll continue to play important roles in the company, however, with Charlie Mills as board chair and Andy Mills and Abrams as vice chairs.

Blackstone, Carlyle and Hellman & Friedman made a multibillion-dollar investment in Medline in 2021, with the Mills family remaining the largest single shareholder. The company used the investment to fund new distribution centers, manufacturing capabilities and IT upgrades. –CN